Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial

• Published in: The Lancet (British edition) 2016-01, Vol.387 (10016), p.349-356
• Main Authors: Lincoff, A Michael, Prof, Mehran, Roxana, Prof, Povsic, Thomas J, MD, Zelenkofske, Steven L, DO, Huang, Zhen, MS, Armstrong, Paul W, Prof, Steg, P Gabriel, Prof, Bode, Christoph, Prof, Cohen, Mauricio G, MD, Buller, Christopher, Prof, Laanmets, Peep, MD, Valgimigli, Marco, MD, Marandi, Toomas, MD, Fridrich, Viliam, MD, Cantor, Warren J, MD, Merkely, Bela, Prof, Lopez-Sendon, Jose, Prof, Cornel, Jan H, MD, Kasprzak, Jaroslaw D, Prof, Aschermann, Michael, Prof, Guetta, Victor, Prof, Morais, Joao, MD, Sinnaeve, Peter R, Prof, Huber, Kurt, Prof, Stables, Rod, DM, Sellers, Mary Ann, MSN, Borgman, Marilyn, BSN, Glenn, Lauren, MS, Levinson, Arnold I, Prof, Lopes, Renato D, MD, Hasselblad, Vic, Prof, Becker, Richard C, Prof, Alexander, John H, Prof
• Format: Article
• Language: English
• Subjects: Acute coronary syndromes; Aged; Angioplasty; Anticoagulants; Anticoagulants - therapeutic use; Aptamers, Nucleotide - therapeutic use; Biomarkers; Cardiology; Cardiovascular disease; Clinical outcomes; Coagulants - administration & dosage; Coronary vessels; Drug Hypersensitivity - epidemiology; Early Termination of Clinical Trials; Europe - epidemiology; Factor IXa - antagonists & inhibitors; Female; Heart attacks; Heart surgery; Hemorrhage - epidemiology; Hirudins; Humans; Internal Medicine; Male; Middle Aged; Mortality; Myocardial infarction; North America - epidemiology; Oligonucleotides - administration & dosage; Patient safety; Peptide Fragments - therapeutic use; Percutaneous Coronary Intervention; Recombinant Proteins - therapeutic use; Stroke; Thrombosis
• ISSN: 0140-6736; 1474-547X
• DOI: 10.1016/S0140-6736(15)00515-2

Summary Background REG1 is a novel anticoagulation system consisting of pegnivacogin, an RNA aptamer inhibitor of coagulation factor IXa, and anivamersen, a complementary sequence reversal oligonucleotide. We tested the hypothesis that near complete inhibition of factor IXa with pegnivacogin during percutaneous coronary intervention, followed by partial reversal with anivamersen, would reduce ischaemic events compared with bivalirudin, without increasing bleeding. Methods We did a randomised, open-label, active-controlled, multicentre, superiority trial to compare REG1 with bivalirudin at 225 hospitals in North America and Europe. We planned to randomly allocate 13 200 patients undergoing percutaneous coronary intervention in a 1:1 ratio to either REG1 (pegnivacogin 1 mg/kg bolus [>99% factor IXa inhibition] followed by 80% reversal with anivamersen after percutaneous coronary intervention) or bivalirudin. Exclusion criteria included ST segment elevation myocardial infarction within 48 h. The primary efficacy endpoint was the composite of all-cause death, myocardial infarction, stroke, and unplanned target lesion revascularisation by day 3 after randomisation. The principal safety endpoint was major bleeding. Analysis was by intention to treat. This trial is registered at ClinicalTrials.gov , identifier NCT01848106 . The trial was terminated early after enrolment of 3232 patients due to severe allergic reactions. Findings 1616 patients were allocated REG1 and 1616 were assigned bivalirudin, of whom 1605 and 1601 patients, respectively, received the assigned treatment. Severe allergic reactions were reported in ten (1%) of 1605 patients receiving REG1 versus one (